Cantor Fitzgerald Has Weak Forecast for BEAM FY2025 Earnings

• MarketBeat Week in Review – 3/4 – 3/8

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a report issued on Wednesday, November 5th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings of ($4.45) per share for the year, down from their previous estimate of ($4.42). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Cantor Fitzgerald also issued estimates for Beam Therapeutics' FY2026 earnings at ($4.18) EPS.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Beam Therapeutics in a research note on Friday, October 10th. Barclays decreased their price objective on Beam Therapeutics from $25.00 to $21.00 and set an "equal weight" rating on the stock in a report on Wednesday, August 6th. Wall Street Zen raised Beam Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 25th. JPMorgan Chase & Co. lowered their price target on shares of Beam Therapeutics from $48.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Beam Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $46.55.

• Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

View Our Latest Research Report on Beam Therapeutics

Beam Therapeutics Trading Up 0.3%

BEAM opened at $23.15 on Friday. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of -5.23 and a beta of 2.40. The business has a 50 day moving average of $23.87 and a 200-day moving average of $20.23. Beam Therapeutics has a 1-year low of $13.52 and a 1-year high of $35.25.

• Is CRISPR Therapeutics the NVIDIA of gene editing?

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.12). The company had revenue of $9.70 million for the quarter, compared to analyst estimates of $12.83 million. Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. The company's revenue for the quarter was down 32.2% on a year-over-year basis. During the same quarter last year, the business earned ($1.17) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BEAM. Vanguard Group Inc. increased its position in Beam Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company's stock valued at $173,256,000 after acquiring an additional 1,249,303 shares in the last quarter. ARK Investment Management LLC boosted its position in Beam Therapeutics by 4.3% in the 2nd quarter. ARK Investment Management LLC now owns 8,847,841 shares of the company's stock valued at $150,502,000 after buying an additional 367,752 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Beam Therapeutics by 2.1% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,830,738 shares of the company's stock valued at $117,242,000 after buying an additional 101,294 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in Beam Therapeutics by 10.7% in the second quarter. Nikko Asset Management Americas Inc. now owns 4,726,799 shares of the company's stock valued at $80,403,000 after acquiring an additional 456,779 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Beam Therapeutics by 72.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,026,701 shares of the company's stock worth $59,112,000 after purchasing an additional 1,273,559 shares during the period. 99.68% of the stock is owned by institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

Featured Articles

• Five stocks we like better than Beam Therapeutics
• 3 Best Fintech Stocks for a Portfolio Boost
• Why Investors Shouldn’t Fear the Dip in Microsoft Stock
• What is diluted earnings per share (Diluted EPS)?
• DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave
• A Deeper Look at Bid-Ask Spreads
• CAVA Stock Looking for Direction After Earnings Miss

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Beam Therapeutics Right Now?

Before you consider Beam Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.

While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here